lexi
IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1789 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
 » Next article
 » Previous article 
 » Table of Contents
  
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »  Article in PDF (43 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

 
In This Article

 Article Access Statistics
    Viewed10730    
    Printed273    
    Emailed25    
    PDF Downloaded1983    
    Comments [Add]    
    Cited by others 10    

Recommend this journal

 


 
EDITORIAL
Year : 2007  |  Volume : 39  |  Issue : 3  |  Page : 123
 

Pharmacovigilance in India


Chief Editor, Indian Journal of Pharmacology, The Chambers. 3rd Floor, Sarkhej-Gandhinagar Highway, Bodakdev, Ahmedabad - 380 054, India

Correspondence Address:
Shiv Prakash
Chief Editor, Indian Journal of Pharmacology, The Chambers. 3rd Floor, Sarkhej-Gandhinagar Highway, Bodakdev, Ahmedabad - 380 054
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.33430

Rights and Permissions



How to cite this article:
Prakash S. Pharmacovigilance in India. Indian J Pharmacol 2007;39:123

How to cite this URL:
Prakash S. Pharmacovigilance in India. Indian J Pharmacol [serial online] 2007 [cited 2022 Jul 6];39:123. Available from: https://www.ijp-online.com/text.asp?2007/39/3/123/33430


We are pleased to publish in this issue an invited article on Pharmacovigilance by Dr. Pipasha Biswas. She is an expert in this subject and the article is well written for readers' understanding of this emerging subject.

I would wish to share with you the recent USFDA safety warning on rosiglitazoine, a drug approved to treat Type 2 diabetes. On 23 rd May, The New England Journal of Medicine rushed out an analysis by prominent cardiologist Steven Nissen, of data about patients taking Avandia (rosiglitazone manufactured by GSK). It suggests they have a 43% higher chance of suffering a heart attack.

We earlier had Vioxx, which created serious adverse events in patients taking this drug. This popular painkiller went on the market in 1999, the same year as Avandia. The same scientist, Nissen, raised some of the earliest concerns that tied Vioxx to higher rates of heart attack and stroke. After Merck finally pulled Vioxx off the market in 2004, an FDA whistle-blower testified that the agency had failed to heed ample warnings.

These examples show that after FDA certifies new drugs as safe and effective based on clinical trials, adverse effects can show up when millions use them. Vioxx caused such problems. So, perhaps, has Avandia. This further testifies the urgent need of a pharmacovigilance program in India for even Generic drugs which are already marketed elsewhere in the world.

Pharmacovigilance has not picked up well in India and the subject is in its infancy. India rates below 1% in pharmacovigilance as against the world rate of 5%. This is due to ignorance of the subject and also lack of training. The office of the Drugs Controller General of India has attempted to implement a pharmacovigilance program in India without much success. A regulation is required to implement the system of reporting adverse events of drugs introduced in the Indian market by pharmaceutical companies. The government has to play an important role in ensuring the availability of safe medicines to the public.



This article has been cited by
1 Acid Dissociation Constants, Enthalpy, Entropy and Gibbs Energy of Bedaquiline by UV-Metric Spectral and pH-Metric Analysis
Milan Meloun, Daniela Cyrmonová, Milan Javurek, Tomáš Pekárek
Journal of Solution Chemistry. 2021; 50(3): 315
[Pubmed] | [DOI]
2 Impact of educational intervention on the knowledge, attitude, and practice of pharmacovigilance among postgraduates of a tertiary care center, Kanchipuram, Tamil Nadu, India
Nithya Panneerselvam, Parimala Kathirvelu, Rajesh Manoharan
Perspectives in Clinical Research. 2021; 0(0): 0
[Pubmed] | [DOI]
3 Present era of drug safety in India: An overview
Royal Patel, Anupam Kumar Sachan, Sanjana Chaohan, Aarti Tiwari, Taruna Giri, Nitish, Abdul Samad Ansari, Rajeshwar Kumar Yadav, Ehraz Mehmood Siddiqui , Shivam Kumar Pandey, Bindu Singh Yadav, Nandini Chaudhary
Journal of Pharmacovigilance and Drug Research. 2021; 2(1): 1
[Pubmed] | [DOI]
4 Effect of Educational Intervention on Adverse Drug Reporting by Physicians: A Cross-Sectional Study
Manisha Bisht,Shruti Singh,D. C. Dhasmana
ISRN Pharmacology. 2014; 2014: 1
[Pubmed] | [DOI]
5 Monitoring of incidence, severity, and causality of adverse drug reactions in hospitalized patients with cardiovascular disease
Kaur, S., Kapoor, V., Mahajan, R., Lal, M., Gupta, S.
Indian Journal of Pharmacology. 2011; 43(1): 22-26
[Pubmed]
6 Regulatory status of banned drugs in India
Shaji, J., Lodha, S.
Indian Journal of Pharmaceutical Education and Research. 2010; 44(1): 86-94
[Pubmed]
7 Patterns of adrs and risk factors involved: Study in cardiology unit of an indian tertiary care center
Kaur, S., Kapoor, V., Mahajan, R., Lal, M., Gupta, S.
Internet Journal of Pharmacology. 2010; 8(1)
[Pubmed]
8 Adverse drug reaction (ADR) notification drop box: an easy way to report ADRs
Dang Amit,Padmanabh V. Rataboli
British Journal of Clinical Pharmacology. 2008; : ???
[Pubmed] | [DOI]
9 Adverse drug reaction (ADR) notification drop box: An easy way to report ADRs
Amit, D., Rataboli, P.V.
British Journal of Clinical Pharmacology. 2008; 66(5): 723-724
[Pubmed]
10 How should you safely outsource pharmacovigilance to an Indian contract research organization?
Edwards, B.
Indian Journal of Pharmacology. 2008; 40(Suppl 1): S 24-S 27
[Pubmed]



 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow